Causes of first hospitalization among 1121 HIV-infected children: Comparison of the pre-Pneumocystis jiroveci pneumonia prophylaxis, pre-antiretroviral therapy and antiretroviral therapy periods

International Journal of STD and AIDS

Volumn 23, Issue 5, 2012, Pages 335-339

  Sudjaritruk, T ^a   Oberdorfer, P ^a   Puthanakit, T ^b   Sirisanthana, T ^c   Sirisanthana, V ^a,c  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

AIDS; Antiretroviral therapy; Causes of hospitalization; Epidemiology; HIV; HIV infected children; Paediatric infection; Thailand

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; BACTERIAL PNEUMONIA; CHILD; CRYPTOCOCCOSIS; FEMALE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION PREVENTION; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOBACTERIOSIS; NEUROCYSTICERCOSIS; NONHUMAN; PENICILLIOSIS; PNEUMOCYSTIS PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SALMONELLOSIS; SCHOOL CHILD; SYSTEMIC MYCOSIS; TOXOPLASMOSIS; TUBERCULOSIS; VIRUS INFECTION;

AGE FACTORS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HOSPITALIZATION; HUMANS; INFANT; MALE; MYCOSES; PARASITIC DISEASES; SURVIVAL ANALYSIS; THAILAND; VIRUS DISEASES;

EID: 84861765977     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2012.011203     Document Type: Article

References (32)

1. Paul S, Gilbert HM, Lande L, et al. Impact of antiretroviral therapy on decreasing hospitalization rates of HIV-infected patients in 2001. AIDS Res Hum Retroviruses 2002;18:501-6
2. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003;362:22-9
3. Charurat M, Blattner W, Hershow R, et al. Changing trends in clinical AIDS presentations and survival among HIV-1-infected women. J Womens Health (Larchmt) 2004;13:719-30
4. Mocroft A, Monforte A, Kirk O, et al. and EuroSIDA study group. Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. HIV Med 2004;5:437-47
5. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med 2005;6:99-106
6. Buchacz K, Baker RK, Moorman AC, et al. and HIV Outpatient Study (HOPS) Investigators. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005. AIDS 2008;22:1345-54
7. Gortmaker SL, Hughes M, Cervia J, et al. and Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001;345:1522-8
8. McConnell MS, Byers RH, Frederick T, et al. and Pediatric Spectrum of HIV Disease Consortium. Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989-2001. J Acquir Immune Defic Syndr 2005;38:488-94
9. Kourtis AP, Bansil P, Posner SF, Johnson C, Jamieson DJ. Trends in hospitalizations of HIV-infected children and adolescents in the United States: analysis of data from the 1994-2003 Nationwide Inpatient Sample. Pediatrics 2007;120:e236-43
10. Mocroft A, Brettle R, Kirk O, et al. and EuroSIDA study group. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002;16:1663-71
11. Palella FJ Jr., Baker RK, Moorman AC, et al. and HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;43:27-34
12. Smit C, Geskus R, Walker S, et al. and CASCADE Collaboration. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006;20:741-9
13. Yang CH, Huang YF, Hsiao CF, et al. Trends of mortality and causes of death among HIV-infected patients in Taiwan, 1984-2005. HIV Med 2008;9:535-43
14. Brady MT, Oleske JM, Williams PL, et al. and Pediatric AIDS Clinical Trials Group219/219C Team. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr 2010;53:86-94
15. Gebo KA, Diener-West M, Moore RD. Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:143-52
16. Fleishman JA, Hellinger FH. Recent trends in HIV-related inpatient admissions 1996-2000: a 7-state study. J Acquir Immune Defic Syndr 2003;34:102-10
17. Krentz HB, Dean S, Gill MJ. Longitudinal assessment (1995-2003) of hospitalizations of HIV-infected patients within a geographical population in Canada. HIV Med 2006;7:457-66
18. Candiani TM, Pinto J, Cardoso CA, et al. Impact of highly active antiretroviral therapy (HAART) on the incidence of opportunistic infections, hospitalizations and mortality among children and adolescents living with HIV/AIDS in Belo Horizonte, Minas Gerais State, Brazil. Cad Saude Publ 2007;23:S414-23
19. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41:1-19
20. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994;43:1-10
21. French MA, Price P, Stone SF. Immune restoration diseases after antiretroviral therapy. AIDS 2004;18:1615-27
22. Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004;38:1159-66
23. Puthanakit T, Oberdorfer P, Akarathum N, Wannarit P, Sirisanthana T, Sirisanthana V. Immune reconstitution syndrome after highly active antiretroviral therapy in HIV-infected Thai children. Pediatr Infect Dis J 2006;25:53-8
24. Puthanakit T, Oberdorfer P, Ukarapol N, et al. Immune reconstitution syndrome from nontuberculous mycobacterial infection after initiation of antiretroviral therapy in children with HIV infection. Pediatr Infect Dis J 2006;25:645-8
25. Thea DM, Lambert G, Weedon J, et al. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group. Pediatrics 1996;97:59-64
26. Rangel MC, Gavin L, Reed C, Fowler MG, Lee LM. Epidemiology of HIV and AIDS among adolescents and young adults in the United States. J Adolesc Health 2006;39:156-63
27. Nachman S, Gona P, Dankner W, et al. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics 2005;115:e488-94
28. Detels R, Tarwater P, Phair JP, et al. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001;15:347-55
29. Dromer F, Mathoulin-Pelissier S, Fontanet A, et al. Epidemiology of HIV associated cryptococcosis in France (1985-2001): comparison of the pre-and post-HAART eras. AIDS 2004;18:555-62
30. Sirisanthana V, Wannarit P, Somsamai R, Pagdi K, Kosonsasitorn R, Khamwangpruek T. Neck masses as a manifestation of mycobacterial immune reconstitution inflammatory syndrome in human immunodeficiency virus-infected children. Chiang Mai Med J 2010;49:67-74
31. Gebo KA, Fleishman JA, Moore RD. Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr 2005;40:609-16
32. Crum-Cianflone NF, Grandits G, Echols S, et al. Infectious Disease Clinical Research Program. Trends and causes of hospitalizations among HIV-infected persons during the late HAART era: what is the impact of CD4 counts and HAART use? J Acquir Immune Defic Syndr 2010;54:248-57